Shares of Wockhardt soared 7 percent to Rs 1,438 apiece on May 30 after the company reported a significant narrowing of its net loss for the March quarter (Q4FY25).
Over the past month, the stock of this drugmaker has jumped 10 percent, as against 2 percent rise in the benchmark Nifty 50 index.
Catch all the market action on our LIVE blog
In Q4FY25, Wockhardt’s net loss narrowed to Rs 45 crore, down from Rs 177 crore a year earlier. The improved bottom line was supported by both revenue growth and a recovery in operational performance.
The company’s revenue rose to Rs 743 crore in Q4FY25, marking a 6 percent year-on-year increase from Rs 700 crore. On the operational front, Wockhardt posted an EBITDA of Rs 64 crore—a notable turnaround from an EBITDA loss of Rs 103 crore in Q4FY24. This marks a return to positive operating margins, indicating tighter cost control and stronger performance across key markets.
For the full financial year (FY25), the company reported a net loss of Rs 57 crore, a significant improvement from a loss of Rs 472 crore in the previous fiscal. Annual revenue rose to Rs 3,012 crore, up from Rs 2,798 crore in FY24.
In a governance update, Wockhardt announced the re-appointment of Akhilesh Krishna Gupta as an Independent Director for a second five-year term. His new tenure will begin on August 29, 2025 and continue until August 28, 2030, pending shareholder approval.
Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
